Our COO Barbara Hubad and Janja Kozjek, Head of GMP Product & Process Development attended the symposium, engaging with leading experts, researchers and industry professionals. The event provided a valuable opportunity to exchange ideas, explore the latest scientific developments and strengthen connections within the international phage therapy community.
By supporting initiatives such as BSVoM, we continue to demonstrate our commitment to driving innovation and contributing to the growth of this rapidly evolving field. We firmly believe that collaboration between academia, industry and healthcare is essential to unlocking the full potential of phage therapy for the future of medicine.
